Severe cases warrant permanent discontinuation of the culprit drugs with the reintroduction of BRAF inhibitors after remission, which is possible.179 Both capmatinib and tepotinib are associated with about 2–6% of drug-induced pneumonitis as per the GEOMETRY and VISION trials, respectively.223–225 Management involves permanent discontinuation of MET inhibitor along with steroid treatment.226 Switching with another TKI after the resolution of pneumonitis can be considered.227. The gene discussed is MET; the disease is pneumonitis.